Latest news

• AZ prepares to file COPD triple, taking on rival GSK

  First to market in Europe was Chiesi with its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, although this has to be administered twice-daily while Trelegy and PT010 are dosed just

• AZ’s COPD triple data sets up market clash with GSK

  In Europe it was pipped to the post by Chiesi, which got a green light for its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, but this medicine must be administered

• With US approval, GSK now needs rapid uptake for COPD triple

  In August, Chiesi won EU approval for its closed triple therapy Trimbow (beclometasone, formoterol and glycopyrronium), but that is administered twice-daily.

• Chiesi Group's Trimbow wins European licence

  European Commission approves the COPD treatment. The European Commission has approved Chiesi Group’s Trimbow to treat adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately ... Alessandro Chiesi, region

• Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

  picked up an approval for a three-drug combination for chronic obstructive pulmonary disorder (COPD) called Trimbow (beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium).